FY2030 EPS Estimates for TSE:ONC Lowered by HC Wainwright

Oncolytics Biotech Inc. (TSE:ONC) – Research analysts at HC Wainwright decreased their FY2030 EPS estimates for shares of Oncolytics Biotech in a research note issued on Wednesday, August 19th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of $0.10 per share for the year, down from their prior estimate of $0.19. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share.

Oncolytics Biotech Price Performance

TSE:ONC opened at C$14.90 on Thursday. The company has a quick ratio of 8.86, a current ratio of 2.88 and a debt-to-equity ratio of 14.58. The business’s 50-day simple moving average is C$14.90 and its two-hundred day simple moving average is C$14.90. The stock has a market cap of C$1.50 billion, a PE ratio of -40.27 and a beta of 0.80. Oncolytics Biotech has a 52 week low of C$0.44 and a 52 week high of C$2.08.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.